The drug Lecanemab [[Leh-canna-mab]] is now undergoing a regulatory approval process in Australia and other countries in the world, but it's exorbitant cost means few will be able to access it.
Can the drug Lecanemab curb the progression of Alzheimers?
Lecanemab is undergoing the regulatory approval process in Australia but the cost means accessibility is an issue - AP.
Get the SBS Audio app
Other ways to listen
The development of the first drug in 30 years that modifies the disease - and not just the symptoms - of the most common form of dementia has given hope to patients. A global large-scale trial testing the use of Lecanemab provided the first evidence of a treatment to slow down the progression of Alzheimer's.
Share
